Biosynex SA
PAR:ALBIO

Watchlist Manager
Biosynex SA Logo
Biosynex SA
PAR:ALBIO
Watchlist
Price: 2.77 EUR -3.82% Market Closed
Market Cap: 29.8m EUR
Have any thoughts about
Biosynex SA?
Write Note

Biosynex SA
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biosynex SA
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Biosynex SA
PAR:ALBIO
Other Current Liabilities
€10.7m
CAGR 3-Years
16%
CAGR 5-Years
46%
CAGR 10-Years
30%
Edap Tms SA
NASDAQ:EDAP
Other Current Liabilities
€6.7m
CAGR 3-Years
34%
CAGR 5-Years
27%
CAGR 10-Years
24%
Biomerieux SA
PAR:BIM
Other Current Liabilities
€600.4m
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
8%
Carmat SA
PAR:ALCAR
Other Current Liabilities
€11k
CAGR 3-Years
-30%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Visiomed Group SA
PAR:ALVMG
Other Current Liabilities
€207k
CAGR 3-Years
-24%
CAGR 5-Years
-42%
CAGR 10-Years
-14%
Amplitude Surgical SA
PAR:AMPLI
Other Current Liabilities
€6.7m
CAGR 3-Years
-8%
CAGR 5-Years
1%
CAGR 10-Years
N/A
No Stocks Found

Biosynex SA
Glance View

Market Cap
28.9m EUR
Industry
Health Care

Biosynex SA engages in the development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.

ALBIO Intrinsic Value
7.73 EUR
Undervaluation 64%
Intrinsic Value
Price

See Also

What is Biosynex SA's Other Current Liabilities?
Other Current Liabilities
10.7m EUR

Based on the financial report for Jun 30, 2024, Biosynex SA's Other Current Liabilities amounts to 10.7m EUR.

What is Biosynex SA's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
30%

Over the last year, the Other Current Liabilities growth was -62%. The average annual Other Current Liabilities growth rates for Biosynex SA have been 16% over the past three years , 46% over the past five years , and 30% over the past ten years .

Back to Top